Forest’s Namenda To Get Label Update After Pediatric Program Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
But Alzheimer’s indication for Namenda and extended-release version will get six months of pediatric exclusivity with a pending NDA for a combo-treatment eligible for the same perks.